**Prif Swyddog Fferyllol**
**Chief Pharmaceutical Officer**

Llywodraeth Cymru
Welsh Government

To:
Chief Executives, Medical Directors and Directors of Pharmacy, Local Health Boards

Cc:
Director, All Wales Therapeutics and Toxicology Centre

By email

Ein cyf/Our ref: MA/JMHSC/1693/25

14 August 2025

Dear Colleague,

**Belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma**

The Welsh Government is committed to ensuring the new and innovative medicines which improve the quality and duration of people's lives are routinely and promptly available to the people of Wales, and that the NHS treats all conditions and diseases equally.

New treatments are normally made available through the New Treatment Fund following publication of Final Draft Guidance by the National Institute for Health and Care Excellence (NICE).

In its appraisal of belantamab mafodotin (Blenrep®) in combination with bortezomib and dexamethasone, for the treatment of relapsed or refractory multiple myeloma after one or more treatments [ID62612], NICE has made a final recommendation for the treatment of the cohort of patients whose prior treatment included lenalidomide and whose condition is refractory to or who cannot tolerate, lenalidomide, at the draft rather than final draft guidance stage.

Belantamab mafodotin is likely to be particularly beneficial for patients in this cohort and NICE has confirmed there are not expected to be any changes to the recommendation for this cohort on publication of final draft guidance later this year.



Parc Cathays • Cathays Park
Caerdydd • Cardiff
CF10 3NQ

e-bost • e-mail:
andrew.evans@llyw.cymru
andrew.evans@gov.wales

Gwefan • website:
www.llyw.cymru
www.gov.wales

Given the status of the recommendation, the innovative nature of this treatment, and the exceptional benefits it offers people in the cohort in question, the Cabinet Secretary for Health and Social Care has today (14 August 2025) agreed health boards in Wales must now make belantamab routinely available in advance of NICE publishing its final draft guidance.  Details of the decision can be found at Decision Reports: 2025 | GOV.WALES.

I would be grateful for your support in ensuring belantamab mafodotin is routinely available for eligible patients in your health board in accordance with the Cabinet Secretary's decision.

Yours sincerely

Andrew Evans FRPharmS
Prif Swyddog Fferyllol/Chief Pharmaceutical Officer
Llywodraeth Cymru/Welsh Government